Form 4: BioLife Solutions Executive Sarah Aebersold Reports Stock Sales Under 10b5-1 Trading Plans

Sarah Aebersold, Chief Human Resources Officer of BioLife Solutions, Inc., reported the sale of common stock between July and September 2024 under pre-arranged 10b5-1 trading plans.

Summary

• Sarah Aebersold, the Chief Human Resources Officer of BioLife Solutions Inc., filed a Form 4 detailing changes in beneficial ownership.
• The report covers multiple sales of common stock executed between July and September 2024.
• These sales were conducted under Rule 10b5-1(c) trading plans adopted by the reporting person at various times to satisfy tax withholding obligations related to the vesting of restricted stock.
• On July 11, 2024, 187 shares were sold at $20.54.
• On July 19, 2024, 300 shares were sold at $21.01.
• On August 21, 2024, 64 shares were sold at $25.61.
• On September 16, 2024, 229 shares were sold at $25.12.
• Following these transactions, Aebersold directly owns 60,903 shares of BioLife Solutions Inc. common stock.

Sentiment

Score: 5

Explanation: The document is a routine regulatory filing detailing stock sales by an executive. The sales were conducted under pre-arranged trading plans, suggesting no particular positive or negative sentiment.

Industry Context

Executive stock sales are a common occurrence, and sales under 10b5-1 plans are generally viewed as less impactful since they are pre-scheduled. However, investors often monitor these filings for insights into executive sentiment and potential future transactions.

Stakeholder Impact

• The stock sales could have a minor impact on shareholders due to the increased supply of shares in the market, but the effect is likely minimal given the relatively small number of shares sold.

Key Dates